Austin, TX, USA and Uppsala, Sweden – 22 January 2024 – A new collaboration between two leading organizations in global medical data has been announced to bring greater efficiency and certainty to regulatory bodies, industry, and the healthcare community, ultimately aiming to improve patient safety worldwide.
Austin, TX – January 16, 2024 – CDISC is proud to announce a research collaboration with the U.S. Food and Drug Administration’s Office of Translational Sciences in the Center for Drug Evaluation and Research and Office of Regulatory Operations in the Center for Biologics Evaluation and Research to incorporate FDA Business Rules into CDISC’s Open Rules Engine (CORE).
Austin, TX – January 2, 2024 – CDISC announces industry veteran Chris Decker is joining the organization as its new President and Chief Executive Officer effective January 2, 2024, succeeding Dave Evans who will be transitioning into retirement after decades of outstanding service to CDISC.
The European Organisation for Research and Treatment of Cancer (EORTC) is pleased to announce a new collaboration with CDISC, a leading provider of data standards in clinical research.
With its Quality of Life measures, EORTC provides the wide research community with questionnaires through which health-related quality of life of cancer patients and survivors can be assessed and their experience put at the forefront.
CDISC invites you to an FDA-hosted public broadcast during the SEND Team’s fall virtual meetings. The broadcast is an opportunity for stakeholders to stay informed on what’s going on with the development of SEND and its use in regulatory submissions, as well as hear from our global SEND user community.
18 October 2023 10:00 – 11:30 am EDT
- Page 1 / 6
- Next page